Ranger® Technology to be presented at Labroots
Source: RNS
Yourgene Health plc
("Yourgene" or the "Company")
Yourgene's Ranger® Technology to be presented at Labroots webinar
Manchester, UK - 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger® Technology, which was acquired with Coastal Genomics Inc in August 2020, will be presented by Yourgene's strategic customer, Labcorp, at the Labroots 2021 Clinical Diagnostics and Research Virtual Symposium Event, taking place on Wednesday 10 November 2021.
During the presentation titled, 'Size selection of cell-free DNA enhances signal for the detection of tumor-specific variants in cancer patients', Kimberly Holden, Research Associate III at Labcorp, will demonstrate how Yourgene's Ranger® Technology is used with the NIMBUS Select platform to overcome historic challenges in circulating tumour DNA (ctDNA) variant detection. The NIMBUS Select is a proprietary instrument combining Yourgene's Ranger® Technology in partnership with the Microlab NIMBUS platform from Hamilton Company, a leading global instrument manufacturer.
Labroots Clinical Diagnostics and Research Virtual Event brings together clinicians, researchers, medical experts and professionals and aims to elevate the level of collaboration and in turn, advance clinical diagnostics, research and medicine. The Labroots event will include presentations on: Emerging Diagnostic Technologies, COVID-19 Screening and Diagnosis, Medical Imaging and The Labs Role in Advancing Equity. Yourgene will also be sponsoring a virtual booth at the event.
Investors can register to dial into the Labroots Webinar here: https://www.labroots.com/virtual-event/clinical-diagnostics-research-2021
|
Yourgene Health plc Lyn Rees, Chief Executive Officer |
Tel: +44 (0)161 669 8122 |
|
|
Barry Hextall, Chief Financial Officer |
|
|
|
Joanne Cross, Director of Marketing |
|
|
|
|
|
|
|
Singer Capital Markets (Joint Corporate Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Aubrey Powell / Tom Salvesen / George Tzimas |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) |
Tel: +44 (0)20 7710 7600 |
|
|
Nicholas Moore / Matthew Blawat / Ben Maddison |
|
|
|
|
|
|
|
Walbrook PR Ltd (Media and Investor Relations) |
Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com |
|
|
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
